<DOC>
	<DOCNO>NCT02222350</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety DS-8500a compare placebo Japanese patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Phase 2 Study DS-8500a Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The objective study evaluate efficacy safety DS-8500a 10 mg 75 mg administer orally , daily , 28 day , compare placebo , Japanese patient Type 2 Diabetes Mellitus double-blind , placebo-controlled parallel-group design . The primary endpoint change 24-hour weighted mean glucose day 28 baseline . The safety , pharmacokinetics , pharmacodynamics DS-8500a evaluate well .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients age ≥ 20 year time inform consent Japanese patient type 2 diabetes Patients HbA1c ≥ 7.0 % &lt; 10.0 % untreated antidiabetic agent . Patients HbA1c ≥ 6.5 % &lt; 9.5 % treat antidiabetic agent . Patients age ≥ 70 year time informed consent Patients history type 1 diabetes diabetic ketoacidosis Patients receive require treatment insulin Patients body mass index ( BMI ) &lt; 18.5 kg/m2 ≥ 35.0 kg/m2 Patients estimate glomerular filtration rate ( eGFR ) , &lt; 45 mL/min per 1.73 m2 Patients fast plasma glucose ≥ 240 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>